Studies have found that systemic treatment with IFN-α and topical treatment with imiquimod (which induces local IFN-α production) both stimulate the development of human psoriasis (152, 153), while inhibition of this signaling pathway can lead to clinical improvement in psoriasis patients (154, 155). The gene discussed is IFNA1; the disease is psoriasis.